TherapeuticsMD (TXMD) Profit After Tax Growth (3y) (2013 - 2026)
TherapeuticsMD (TXMD) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 27.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.40% |
| Mar 31, 2026 | 26.54% |
| Dec 31, 2025 | -26.06% |
| Sep 30, 2025 | 26.06% |
| Jun 30, 2025 | -83.01% |
| Mar 31, 2025 | 76.29% |
| Dec 31, 2024 | 26.05% |
| Sep 30, 2024 | 77.13% |
| Jun 30, 2024 | 70.54% |
| Mar 31, 2024 | 73.49% |
| Dec 31, 2023 | 72.42% |
| Sep 30, 2023 | 53.04% |
| Jun 30, 2023 | 64.05% |
| Mar 31, 2023 | 60.13% |
| Dec 31, 2022 | 73.51% |
| Sep 30, 2022 | 22.93% |
| Jun 30, 2022 | 59.17% |
| Mar 31, 2022 | -7.46% |
| Dec 31, 2021 | -2.93% |
| Sep 30, 2021 | -10.02% |